Cargando…

Non-Small-Cell Lung Cancer: New Rare Targets—New Targeted Therapies—State of The Art and Future Directions

SIMPLE SUMMARY: The use of novel therapeutic drugs in lung cancer has changed the paradigm of the diagnosis and treatment of lung cancer. Due to the development of advanced diagnostic procedures (e.g., next generation sequencing (NGS)) around half of non-small-cell lung cancer (NSCLC) patients can b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stencel, Katarzyna, Chmielewska, Izabela, Milanowski, Janusz, Ramlau, Rodryg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070470/ https://www.ncbi.nlm.nih.gov/pubmed/33921237 http://dx.doi.org/10.3390/cancers13081829

Ejemplares similares

Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience
por: Chmielewska, Izabela, et al.
Publicado: (2021)

Anti-angiogenic agents in the treatment of non-small cell lung cancer
por: Szyszka-Barth, Katarzyna, et al.
Publicado: (2014)

Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma
por: Rybarczyk-Kasiuchnicz, Agnieszka, et al.
Publicado: (2021)

Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
por: Nicoś, Marcin, et al.
Publicado: (2019)

Current views on molecularly targeted therapy for lung cancer – a review of literature from the last five years
por: Rybarczyk-Kasiuchnicz, Agnieszka, et al.
Publicado: (2018)

Small Cell Lung Cancer in the Course of Idiopathic Pulmonary Fibrosis—Case Report and Literature Review
por: Grodkiewicz, Maria, et al.
Publicado: (2022)

Impact of copy number variant and single nucleotide polymorphism of the programmed death-ligand 1 gene, programmed death-ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non-small cell lung carcinoma
por: Grenda, Anna, et al.
Publicado: (2021)

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
por: Bożyk, Aleksandra, et al.
Publicado: (2021)

Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
por: Krzyżanowska, Natalia, et al.
Publicado: (2022)

Actual status of therapeutic vaccination in non-small cell lung cancer
por: Szyszka-Barth, Katarzyna, et al.
Publicado: (2014)

The analysis of ALK gene rearrangement by fluorescence in situ hybridization in non-small cell lung cancer patients
por: Wojas-Krawczyk, Kamila, et al.
Publicado: (2013)

An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient
por: Krukowska, Kinga, et al.
Publicado: (2020)

Breaking the ‘Undruggable’ Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with KRAS Mutations—A Comprehensive Review and Description of Single Site Experience
por: Chmielewska, Izabela, et al.
Publicado: (2023)

The Incidence of EGFR-Activating Mutations in Bone Metastases of Lung Adenocarcinoma
por: Krawczyk, Paweł, et al.
Publicado: (2013)

Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with EGFR Gene Mutation–Case Report and a Literature Review
por: Rekowska, Anna, et al.
Publicado: (2022)

The Application of Real-Time PCR Technique to Detect Rare Cell Clones with Primary T790M Substitution of EGFR Gene in Metastases of Non-small Cell Lung Cancer to Central Nervous System in Chemotherapy Naive Patients
por: Powrózek, Tomasz, et al.
Publicado: (2014)

State of the Art in the Current Management and Future Directions of Targeted Therapy for Differentiated Thyroid Cancer
por: Silaghi, Horatiu, et al.
Publicado: (2022)

Residential Radon Exposure in Patients with Advanced Lung Cancer in Lublin Region, Poland
por: Grzywa-Celińska, Anna, et al.
Publicado: (2022)

The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients
por: Kucharczyk, Tomasz, et al.
Publicado: (2015)

The smell of death. State-of-the-art and future research directions
por: Cieśla, Julia, et al.
Publicado: (2023)

Erlotinib in salvage treatment of patients with advanced non-small cell lung cancer: results of an expanded access programme in Poland
por: Kowalski, Dariusz M., et al.
Publicado: (2012)

Vaccine Development against Infectious Diseases: State of the Art, New Insights, and Future Directions
por: Conceição Silva, Fatima, et al.
Publicado: (2023)

Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy
por: Grodzka, Anna, et al.
Publicado: (2023)

Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?
por: Krzyżanowska, Natalia, et al.
Publicado: (2022)

Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
por: Krawczyk, Paweł, et al.
Publicado: (2014)

In vitro preliminary study on different anti-PD-1 antibody concentrations on T cells activation
por: Wieleba, Irena, et al.
Publicado: (2022)

Soil ecotoxicology: state of the art and future directions
por: van Gestel, Cornelis A.M.
Publicado: (2012)

Micronucleus Assay: The State of Art, and Future Directions
por: Sommer, Sylwester, et al.
Publicado: (2020)

Hemorrhoids Embolization: State of the Art and Future Directions
por: Rebonato, Alberto, et al.
Publicado: (2021)

Treatment resistance in psychiatry: state of the art and new directions
por: Howes, Oliver D., et al.
Publicado: (2021)

Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy
por: Hirsh, Vera, et al.
Publicado: (2007)

Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system
por: Strzelec, Martyna, et al.
Publicado: (2023)

Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non‐small cell lung cancer patients
por: Grenda, Anna, et al.
Publicado: (2019)

Presence of Akkermansiaceae in gut microbiome and immunotherapy effectiveness in patients with advanced non-small cell lung cancer
por: Grenda, Anna, et al.
Publicado: (2022)

Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives
por: Kwok, Marwan, et al.
Publicado: (2021)

The current state of the art and future trends in RAS-targeted cancer therapies
por: Punekar, Salman R., et al.
Publicado: (2022)

Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non-small cell lung cancer to the central nervous system
por: KRAWCZYK, PAWEŁ, et al.
Publicado: (2013)

Nanoparticles in explosives detection – the state-of-the-art and future directions
por: Peveler, William J., et al.
Publicado: (2017)

AI in Health: State of the Art, Challenges, and Future Directions
por: Wang, Fei, et al.
Publicado: (2019)

Simulation Training in Urology: State of the Art and Future Directions
por: Canalichio, Katie Lynn, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5ohoutsloqbqd4rm402k8ptplc